C. H. Bowden

发表

An open‐label, long‐term evaluation of the safety, efficacy and tolerability of avanafil in male patients with mild to severe erectile dysfunction

I. Goldstein, A. McCullough, L. Belkoff, 2013, International journal of clinical practice.

A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.

J. Moul, K. McVary, J. Mulhall, 2013, The Journal of urology.

WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE

M. Davidson, W. Day, C. H. Bowden, 2011 .

Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus.

I. Goldstein, C. Peterson, L. Belkoff, 2012, Mayo Clinic proceedings.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction.

I. Goldstein, W. Hellstrom, A. McCullough, 2012, The journal of sexual medicine.

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunctionjsm_2629 1..12

I. Goldstein, W. Hellstrom, A. McCullough, 2012 .

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

K. Gadde, D. Allison, D. Ryan, 2011, The American journal of clinical nutrition.

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

P. McCullough, K. Didonato, C. H. Bowden, 2012, Sleep.

Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.

I. Goldstein, W. Hellstrom, J. Tursi, 2015, The Journal of urology.

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).

S. Oparil, S. Tonstad, M. Davidson, 2013, The American journal of cardiology.